Navigation Links
Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid
Date:7/17/2009

TSX: BMR

TORONTO, July 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (TSX: BMR) ("Bradmer" or the "Corporation") announced today that its Board of Directors has authorized the Corporation to proceed with a substantial issuer bid (the "Offer"), pursuant to which the Corporation will offer to purchase for cancellation up to 8,300,000 million of its outstanding common shares ("Shares") at a price of Cdn$0.20 (approximately US$0.1788) per Share. The funds required to pay for Shares purchased pursuant to the Offer, and the payment of the fees and expenses of the Offer, will be funded by Bradmer out of cash on hand.

"While we continue to pursue an appropriate business strategy for our Neuradiab(R) asset, the decision to provide shareholders with an opportunity to divest of their position reflects the current challenging capital markets as well as the illiquidity of the Shares," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "We are not providing guidance to shareholders on this matter. The Offer is consistent with our strategy adopted in February 2009 to mitigate future risks and we believe does so in a manner that treats all shareholders equally. We continue to evaluate opportunities to maximize the value of the Neuradiab asset, however a substantial portion of the existing cash on hand will be utilized to ensure Bradmer is left with no future obligations or liabilities."

As of July 17, 2009, there were 13,488,215 Shares issued and outstanding. Assuming that the Offer is fully subscribed, the Offer will result in the purchase by Bradmer of 8,300,000 Shares, representing approximately 61.5% of the total number of issued and outstanding Shares. If more than 8,300,000 Shares are deposited under the terms of the Offer, and Shares are taken up pursuant to the Offer, Bradmer will purchase the Shares on a pro rata basis according to the number of Shares deposited by each shareholder.

The Of
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Bradmer announces 2009 first quarter operational and financial results
2. Bradmer announces 2008 fourth quarter and fiscal year operational and financial results
3. Bradmer implements cash conservation plan
4. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
5. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
6. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
7. Bradmer announces 2008 third quarter operational and financial results
8. Bradmer to present at Rodman & Renshaw Healthcare Conference
9. Bradmer receives FDA approval to proceed with Phase III clinical trial
10. Bradmer announces 2008 first quarter operational and financial results
11. Bradmer announces new additions to management team
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6CompuCyte Announces the Release of Four-Laser Imaging Cytometers 2CardioVascularCS Org a division of EndoVascular Forum Inc Partners with Complex Interventional Cardiovascular Therapy 28CICT 29 to Extend Electro 4519 1CardioVascularCS Org a division of EndoVascular Forum Inc Partners with Complex Interventional Cardiovascular Therapy 28CICT 29 to Extend Electro 4519 2CardioVascularCS Org a division of EndoVascular Forum Inc Partners with Complex Interventional Cardiovascular Therapy 28CICT 29 to Extend Electro 4519 3NASA Selects Four Proposals to Study Space Radiation Risks 47661 1NASA Selects Four Proposals to Study Space Radiation Risks 47661 2New Program May Help Teens at High Risk for Depression 47656 1New Program May Help Teens at High Risk for Depression 47656 2New Program May Help Teens at High Risk for Depression 47656 3